Last Posted: Aug 27, 2019
- Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases
NCI, August 26, 2019 - Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden
D Bomze et al, JAMA Oncology, August 22, 2019 - Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1
JS Lee et al, JAMA Oncology, August 22, 2019 - Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD-L1 immunotherapy.
Wu Chih-Hsun et al. Cancer medicine 2019 Aug - The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma.
Chen Hao et al. Oncoimmunology 2019 8(8) 1608132 - Tumor mutation burden: from comprehensive mutational screening to the clinic.
Galuppini Francesca et al. Cancer cell international 2019 19209 - Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.
Wang Feng et al. JAMA oncology 2019 Aug - Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology.
Dyrskjøt Lars et al. Current opinion in urology 2018 28(6) 598-603 - Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.
Wu Hao-Xiang et al. Journal for immunotherapy of cancer 2019 Aug 7(1) 206 - Oncologist uptake of comprehensive genomic profile guided targeted therapy.
Nesline Mary K et al. Oncotarget 2019 Jul 10(45) 4616-4629
.png)
No hay comentarios:
Publicar un comentario